Surfactant Protein Genetic Variants in COVID-19 Infection
NCT ID: NCT04650191
Last Updated: 2022-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2020-03-01
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children
NCT06902194
Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study
NCT04618861
Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19
NCT06142279
Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
NCT05638932
COVID-19 Infection in Patients With Chronic Pulmonary Diseases.
NCT05087199
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mild COVID-19 infection
Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
Identification of genetic variants
DNA will be extracted from whole blood from study subjects
Moderate COVID-19 infection
Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
Identification of genetic variants
DNA will be extracted from whole blood from study subjects
Severe COVID-19 infection
Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
Identification of genetic variants
DNA will be extracted from whole blood from study subjects
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Identification of genetic variants
DNA will be extracted from whole blood from study subjects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
1 Day
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Milton S. Hershey Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chintan Gandhi
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Milton S. Hershey Medical center
Hershey, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15456
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.